Drug Discovery World

MARCH 12, 2024

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. This is part of a series of predictions based on different themes.

Molecular Biology 204

Molecular Biology Small Molecule Therapies FDA Approval 204

Drug Discovery World

MAY 1, 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Artificial intelligence (AI) AI is on everyone’s minds as we head into 2024; of course, this is across not just the drug discovery spectrum but is particularly relevant to therapeutic antibodies.

FDA Approval 147

FDA Approval Therapies FDA Molecular Biology 147

Drug Discovery World

MARCH 12, 2024

MJ : From the first known reference to medicinal use of plants on a Mesoptamian clay tablet written during the third millennium BC to the FDA approval of the blockbuster anticancer drug Taxol in the 1990s, natural products from plants have been at the forefront of efforts to overcome human diseases, such as cancers, hypertension, and pain.

Small Molecule 147

Small Molecule Synthetic Chemistry Production Molecular Biology 147

Drug Target Review

FEBRUARY 15, 2024

Advances in molecular biology have led to highly safe, efficient, and effective platforms, such as mRNA, that can be rapidly re-purposed for different pathogens, multiple pathogens, or new strains of evolving pathogens. 2023 [cited 2024 Jan 22]. 2023 [cited 2024 Jan 22]. 2019 [cited 2024 Jan 22]. 29, 2023] | U.S.

Drug Development 122

Drug Development Virus Vaccine Government 122